Lyratzopoulos, G; Barbiere, JM; Rachet, B; Baum, M; Thompson, MR; Coleman, MP (2011) Changes over time in socioeconomic inequalities in breast and rectal cancer survival in England and Wales during a 32-year period (1973-2004): the potential role of health care. ABSTRACT INTRODUCTION: Socioeconomic inequalities in cancer survival are well documented but they differ for different cancers and over time. Reasons for these differences are poorly understood. PATIENTS AND METHODS: For England and Wales, we examined trends in socioeconomic survival inequalities for breast cancer in women and rectal cancer in men during the 32-year period 1973-2004. We used a theoretical framework based on Victora's 'inverse equity' law, under which survival inequalities could change with the advent of successive new treatments, of varying effectiveness, which are disseminated with different speed among patients of different socioeconomic groups. We estimated 5year relative survival for patients of different deprivation quintiles and examined trends in survival inequalities in light of major treatment innovations. RESULTS: Inequalities in breast cancer survival (921,611 cases) narrowed steadily during the study (from -10% to -6%). In contrast, inequalities in rectal cancer survival (187,104 cases) widened overall (form -5% to -11%) with fluctuating periods of narrowing inequality. CONCLUSION: Trends in socioeconomic differences in tumour or patient factors are unlikely explanations of observed changes over time in survival inequalities. The sequential introduction into clinical practice of new treatments of progressively smaller incremental benefit may partly explain the reduction in inequality in breast cancer survival.
INTRODUCTION
Wide socioeconomic inequalities in survival have been reported for many cancers. [1, 2] Evidence on the causes of these inequalities remains limited, but they may at least partly reflect differences in clinical management (the 'healthcare factors' hypothesis). [1, 2] If this hypothesis were correct, socioeconomic inequalities should be largely determined by socio-economic differences in the quality of treatment received, with deprived patients more often managed sub-optimally. Directly examining this hypothesis is difficult, however, because the treatment information routinely collected by cancer registries, at least historically, is usually in the form of binary (yes/no) information about the main treatment modalities (surgery, radiotherapy, chemotherapy) given within six months of diagnosis, with no information on the timeliness and technical excellence of surgery, or the timeliness, nature, dose and sequencing of radiotherapy or chemotherapy regimes.
An alternative approach is to examine long-term trends in survival inequalities to identify whether the 'advent' of major new treatments was followed by narrowing or widening of inequalities in survival. We use the term 'advent' to denote the timing of market authorisation of new drug therapies; or of the introduction into clinical practice of new surgical and radiotherapy techniques, also often associated with peer-reviewed publication of 'key' relevant studies. This approach is inferior to direct examination of the impact of new treatments on survival using individual patient data, but it may provide insights into the interpretation of historical changes in survival inequalities during periods when population-based cancer treatment data were absent or rudimentary.
The 'inverse equity law' is a conceptual framework, proposed by Victora and colleagues, [3] as an extension of Hart's 'inverse care law', [4] within which the advent of a single new treatment may generate healthcare inequalities that are later resolved.
According to this framework, inequality in use of a specific healthcare intervention widens soon after its introduction but later narrows, until it ceases to exist ( Figure 1 ).
Evidence exists for time-lagged dissemination of new interventions among lower
socioeconomic groups for cervical cancer screening, [5] measles, mumps and rubella (MMR) immunisation, [6] and primary care quality improvements for chronic diseases other than cancer. [7] Applying Victora's framework to cancer care is challenging, as it typically involves combinations of different treatment modalities (e.g. surgery, chemotherapy or radiotherapy).
Step-wise but marginal improvements in survival following introduction of a new drug, for example, may be difficult to detect against underlying trends attributable to refinement and wider dissemination of older treatments, or to improvements in the organisation of services. Testicular cancer provides a rare example of very rapid improvement in survival outcomes soon after the introduction of a single, new and highly effective treatment, platinum-based chemotherapy, in the 1970s. [8] Newer cancer treatments are now introduced into clinical practice frequently, so identifying the treatment(s) responsible for socio-economic inequalities in survival at any point in time may be difficult. Moreover, socio-economic inequalities in access to newer treatments may be arising at the same time that inequalities in the use of more established treatments are being resolved ( Figure 1 ). For these reasons, the evolving causes of inequality in cancer survival, and the likely role of specific healthcare interventions at different times, may be difficult to establish with precision. The relative effectiveness of new vs. existing treatments is also relevant. If newer treatments are much more effective than existing ones, inequalities in survival are likely to widen, whereas if newer treatments are only marginally more effective, then inequalities in outcomes are likely to narrow.
We examined changes in socioeconomic inequalities in survival for breast cancer in women and rectal cancer in men in England and Wales over the 32-year period 1973-2004 . We chose these cancers because they are common, and because socioeconomic inequalities in survival became narrower during the 1980s and 1990s for breast cancer, but became wider for rectal cancer. [9, 10] We also examined whether any inflection in the underlying survival trends (and socio-economic inequalities) could be linked to the advent of new treatments considered to have been major advances in cancer management during this period. Figure 1 . When an effective new treatment (A) first becomes available, its use is initially higher among more affluent patients. Later, uptake increases among more deprived patients, eventually catching up with levels in affluent groups. Equal use of the treatment is reached after a lag period has elapsed. However the cycle may start again, for another, newer, treatment (B), giving rise to another inequality-equality lag cycle, and perpetuating socio-economic inequalities in healthcare. [16] and with the hybrid approach for patients diagnosed in 2007. [17] Stratification by year of diagnosis (32 years) and deprivation (5 categories) produced 160 strata, and even with these very common cancers, the precision of year-on-year survival estimates was reduced, so trends were smoothed with five-year moving averages.
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We estimated trends in relative survival at one year and five years after diagnosis, and at five years conditional upon one-year survival, for each deprivation group. For brevity, only the plots of five-year survival for the least and most deprived groups are presented in the article. Absolute deprivation gaps in five-year survival were calculated as the simple differences between the fitted survival estimates for the most and the least deprived groups derived from a linear regression model. These were displayed graphically and inspected for temporal change in survival inequalities.
RESULTS
Data for 921,611 women with breast cancer and 187,104 men with rectal cancer diagnosed during the period 1971-2006 were included in the analyses.
For women with breast cancer, five-year relative survival improved steadily from 55% to 85% between 1973 and 2004. Survival improved in each deprivation group, and the deprivation gap in survival has narrowed gradually over most of the 32-year period (from -10% to nearly -6%), except for two brief periods in the early 1980s and early 1990s, during which it was more stable (Figure 2 ).
During the study period, adjuvant chemotherapy had been shown to be effective originally in 1976 and with an increasingly supportive evidence basis thereafter during the 1980's. [18, 19] Similarly, endocrine therapy had been shown to be effective during the 1980's, [18] with evidence also emerging from UK trials. [20, 21] The UK breast cancer screening programme was introduced gradually from 1988 to 1993. [22] Five-year relative survival for men with rectal cancer improved from 29% to 53% between 1973 and 2004 ( Figure 3 ). Survival increased in each deprivation group, but not at the same pace, and the survival deficit has widened from -5% to -11% since the 1970s. Two distinct 'cycles' can be seen. The deprivation gap in survival narrowed slightly in the late 1970s but then widened even more by the mid-1980s; a second 'cycle' of this type occurred between the late 1980s and the early 1990s, and the deprivation gap has remained greater than -10% since the late 1990s. 
DISCUSSION
We report contrasting long-term trends in socio-economic inequalities in survival for two during the examined study period. We know of no evidence detailing such 'convergence' or 'divergence' in socioeconomic differences in risk factor exposure or tumour type for either breast or rectal cancer. Moreover, in relation to rectal cancer, socioeconomic differences in exposure to risk factors associated with more aggressive (poorer prognosis) tumour types ought not only to have been substantial initially, but should have also changed 'direction' twice during a period prior and during the study.
Therefore, although we acknowledge that socioeconomic differences in tumour biology could account for a proportion of the observed differences in survival inequalities, we believe they are unlikely to represent a substantial cause of the observed substantial changes over time in survival inequalities in major part.
Differential changes in the co-morbidity burden of cancer patients of different socioeconomic groups are also an unlikely explanation. Co-morbidity affects clinical decisions about treatment suitability; some research also postulates that it could lower host resistance to cancer. [33] No data were available on co-morbidity in the cancer patients we studied, but there is evidence of either stable or widening inequalities in general fitness and co-morbidity in both sexes during the study period. [34, 35, 36] Although widening inequalities in co-morbidity could perhaps have contributed to widening inequalities in rectal cancer survival, it would be hard for this to explain narrowing inequalities in breast cancer survival, as co-morbidities constraining treatment The introduction of breast cancer screening during the study period has contributed to distinct improvement in relative survival. [37] It is however unlikely that the introduction of breast screening could have contributed to narrowing survival inequalities, as screening uptake has been slightly higher among more affluent patients, [38, 39] and therefore the net effect of such uptake differences could not have contributed the observed narrowing of survival inequalities.
Having considered the potential role of changes over time in socioeconomic differences in respect of tumour and patient factors, and in competing mortality, we would wish to draw attention to the potential role of socioeconomic differences in the speed of dissemination of newer treatments among patients of different deprivation groups during the study period. Given the study period, we were not able to take into account in the analysis any information on the actual treatment provided to patients. For more recent periods, and prospectively, it is hoped that use of linked datasets (e.g. of cancer registration with Hospital Episodes Statistics data) could help more accurately depict treatment patterns in the future (including information on the timeliness, nature and 'dose' of treatments). [40] A key consideration is that following Victora's hypothesis survival inequalities can be considered to be the final product of successive inequality phases in relation to treatments introduced in temporal sequence. Therefore, whether inequalities get narrower or wider is determined by whether successive innovations in management are more or less effective compared with previous and subsequent treatment innovations.
Adjuvant chemotherapy, endocrine therapy (tamoxifen) and breast cancer screening were all introduced during the study period. Most (i.e. about two thirds) of the observed reduction in breast cancer mortality in England and Wales between 1971 and 1997 is attributable to wider availability and use of chemotherapy and endocrine therapy, as opposed to earlier diagnosis because of screening. [37] Concordant findings have been observed in the USA , [41] and Norway, [42] and also in Australia (1981) (1982) (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) where substantial improvement in survival had been achieved before screening programmes were introduced.[43] Therefore, the most effective (in terms of effect size) treatments for breast cancer during the study period appear to have been those relatively 'old' (but comparatively more effective) treatments gradually introduced in clinical practice during the 1970s and 1980s. Both adjuvant chemotherapy and endocrine therapy are associated with up to 30% reduction in mortality, an effect size substantially larger to that derived by screening (15%). [44] If a newer treatment is less effective than an older one, survival inequality may narrow over time, because the lapse of a 'lag' period eventually enables equal use of the older and more effective treatment.
The degree of 'inequality resolution' resulting from this change exceeds the 'inequality generation' resulting by the introduction of the newer (but less effective) treatment.
Whilst a degree of inequality may prevail for relatively new interventions (such as breast cancer screening), [38, 39] if their effect size is smaller than that of other, 'older'
interventions, the net effect will be progressive narrowing of inequalityas observed in our study. Reduction of geographical inequalities in breast cancer survival between different regions against the background of improving overall population survival, were described in Denmark, reminiscent of our own findings, [45] which also concord with Australian research. [46] Evidence from The Netherlands confirms substantial changes in clinical management during the study period. [47] Regarding rectal cancer, it has been postulated previously that widening survival inequalities for rectal cancer between 1986 and 1999 may have been caused by a combination of a differential socioeconomic trends in earlier diagnosis and clinical management. [48] Rectal cancer provides a good example of the multi-modality of cancer management, with several tests and treatments being of great relevance to clinical managementmost of which have been introduced and disseminated into clinical practical gradually during the study period. Unlike breast cancer, it would appear that the succession of innovative treatments was 'from less to more efficacious', resulting in widening inequality. However, the relatively large number of innovations in rectal cancer management during the study period makes the detection of their direct impact on population survival (in the absence of direct empirical prospective evidence on treatment use) challenging.
We have used five-year relative survival. Trends in survival inequality can also be compared for any other time period, e.g. one-year, three-year and five-year conditional upon one-year survival. We have indeed calculated such survival estimates, but on inspection, it was apparent there was no added value in presenting such analyses. We opted to focus on inequalities in survival (as opposed in hazard of death) as survival is the most commonly used metric of population-based outcomes in cancer care, and so that our findings can be understood and interpreted more immediately by researchers, members of the public, and policy makers. [49] Although in principle the choice of absolute or relative measures of inequality could give different interpretations, [50, 51] in our own study examining relative differences in survival identifies similar change patterns over time. There is no universal acceptance of consistently using either absolute or relative inequality measures, reason for which presenting actual (socioeconomic group specific) rates, as opposed to only presenting summary inequality measures such as rate differences or ratios is recommended, [50, 51] and this is why we present actual rates as well as summary measures in our study.
We have examined and report opposing (narrowing-widening) inequality trends during a 32-year period for two common cancers and explored the potential role of different explanatory factors, and healthcare factors in particular. Although the analysis relates to historical data, our findings could hold valuable lessons for policy makers of the present day. Ongoing investment in prospective national audit datasets and registries could help to track diffusion of effective innovation in cancer treatment more effectively than it has been possible in the past, and help detect potential variation in use among different population subgroups. Such policy initiatives that could enable the 'early detection' of inequality in process measures such as treatment use, help 'reduce' the length of 'natural' treatment inequality lags resulting from the introduction of new treatments, and accelerate the reduction of historical or prevent the generation of future inequalities in outcomes. Further studies including prospective data collection of treatment details could help amplify the empirical basis supporting the interpretation framework about social inequalities in survival that we propose in this paper. 
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